SCHEMBL2760198

SCHEMBL2760198

CCCc1nc(C(C)(C)C)cs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.40
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
ALDH1A1 P00352 3/20 0.39
CCR4 P51679 6/20 0.39
LMNA P02545 2/20 0.38
SLC6A3 Q01959 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36
STAT1 P42224 1/20 0.36
ATAD2 Q6PL18 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
HPGD P15428 1/20 0.34
DRD2 P14416 1/20 0.34
HRH1 P35367 1/20 0.34
POLB P06746 2/20 0.33
NPC1 O15118 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16592087 0.89 SLC6A3 (0.40) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL2608448 0.83 LMNA (0.43) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL28860776 0.82 LMNA (0.36) HTR2AALDH1A1LMNASLC6A3MEN1
SCHEMBL18469815 0.80 HTR1A (0.42) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL13064847 0.79 SLC6A3 (0.35) HTR2ASLC6A3DRD2HRH1
SCHEMBL2736380 0.78 HTR1A (0.41) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL5775322 0.78 HTR1A (0.41) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL4573687 0.78 HTR1A (0.41) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL5908628 0.78 HTR1A (0.41) HTR2AHTR1AHTR7ALDH1A1CCR4
SCHEMBL12263961 0.75 HTR1A (0.41) HTR2AHTR1AHTR7ALDH1A1CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11000526-B2 Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2021-05-11 US disclosed
US-20190298725-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS RUGEN HOLDINGS (CAYMAN) LIMITED (KY) 2019-10-03 US disclosed
US-10183015-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES LLC (US) 2019-01-22 US disclosed
US-10030016-B2 Heterocyclic compounds useful as PDK1 inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2018-07-24 US disclosed
US-20180028518-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2018-02-01 US disclosed
US-20180028518-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES LLC 2018-02-01 US disclosed
US-9670172-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2017-06-06 US disclosed
US-9670172-B2 Heterocyclic compounds and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2017-06-06 US disclosed
US-20150065519-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES LLC 2015-03-05 US disclosed
US-8088766-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA INC. (US) 2012-01-03 US disclosed
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-12-30 US disclosed
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11000526-B2 Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders GRIN2A, GRIN1, GRIN2B HTR2A 77/4885HTR1A 75/4885HTR7 131/4885
US-20190298725-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS GRIN2A, GRIN1, GRIN2B HTR2A 77/4885HTR1A 75/4885HTR7 131/4885
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ERBB2, GRB2, EGFR HTR2A 717/4885HTR1A 2378/4885HTR7 1957/4885
US-20150065519-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE HRAS, VHL, ESRRB HTR2A 681/4885HTR1A 1084/4885HTR7 710/4885
US-20180028518-A1 Heterocyclic Compounds and Methods of Use LIPC, CPT1A, FABP1 HTR2A 4114/4885HTR1A 4362/4885HTR7 4100/4885
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES DDT, ACHE, TPM3 HTR2A 963/4885HTR1A 459/4885HTR7 1866/4885
US-10030016-B2 Heterocyclic compounds useful as PDK1 inhibitors PDK1, PDK2, PDK3 HTR2A 4784/4885HTR1A 4799/4885HTR7 4729/4885
US-10183015-B2 Heterocyclic compounds and methods of use LIPC, CPT1A, FABP1 HTR2A 4114/4885HTR1A 4362/4885HTR7 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.